✨
AI Summary
- Poseida Therapeutics CEO Mark Gergen discusses the shift from AAV to nanoparticle delivery.
- Hurdles in developing off-the-shelf therapies and manufacturing challenges are explored.
- The company shares strategies for overcoming production obstacles.
Guests on This Episode
MG
Mark Gergen
1 podcast appearance